At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ELDN Eledon Pharmaceuticals, Inc.
Market Closed 10-30 16:00:00 EDT
2.77
-0.27
-8.88%
盘后2.93
+0.16+5.68%
19:57 EDT
High3.04Low2.75Vol1.27M
Open2.99D1 Closing3.04Amplitude9.70%
Mkt Cap225.09MTradable Cap206.55MTotal Shares81.26M
T/O3.58MT/O Rate1.70%Tradable Shares74.57M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Eledon’s Tegoprubart Improves Quality of Life Versus Tacrolimus in Phase 2 Kidney Transplant Trial
Reuters  ·  10-26
Eledon’s Tegoprubart Improves Quality of Life Versus Tacrolimus in Phase 2 Kidney Transplant Trial
Eledon Pharmaceuticals Presents Phase 2 Bestow Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting
THOMSON REUTERS  ·  10-26
Eledon Pharmaceuticals Presents Phase 2 Bestow Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting
Eledon to Present Phase 2 Bestow Kidney Transplant Trial Patient-Reported Outcomes for Tegoprubart at ASN Kidney Week 2026
Reuters  ·  10-06
Eledon to Present Phase 2 Bestow Kidney Transplant Trial Patient-Reported Outcomes for Tegoprubart at ASN Kidney Week 2026
Eledon Shares Rise on Fast-Track Designation for Kidney Treatment
Dow Jones  ·  09-23
Eledon Shares Rise on Fast-Track Designation for Kidney Treatment
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Viking Therapeutics (VKTX) and Amgen (AMGN)
TIPRANKS  ·  09-22
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Viking Therapeutics (VKTX) and Amgen (AMGN)
Eledon Reports 24-Month Phase 2 Bestow Extension Data Showing Higher eGFR with Tegoprubart vs Tacrolimus in Kidney Transplant Patients
Reuters  ·  09-22
Eledon Reports 24-Month Phase 2 Bestow Extension Data Showing Higher eGFR with Tegoprubart vs Tacrolimus in Kidney Transplant Patients
Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results at the International Congress of the Transplantation Society
THOMSON REUTERS  ·  09-22
Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results at the International Congress of the Transplantation Society
Top Premarket Gainers
MT Newswires Live  ·  09-11
Top Premarket Gainers
Eledon to Present Long-Term Tegoprubart Data at Transplantation Society Congress
Reuters  ·  09-09
Eledon to Present Long-Term Tegoprubart Data at Transplantation Society Congress
Analysts’ Top Healthcare Picks: Align Tech (ALGN), Eledon Pharmaceuticals (ELDN)
TIPRANKS  ·  09-03
Analysts’ Top Healthcare Picks: Align Tech (ALGN), Eledon Pharmaceuticals (ELDN)
Eledon Submits FDA IND for Tegoprubart Islet Cell Transplant Trial in Type 1 Diabetes
Reuters  ·  09-03
Eledon Submits FDA IND for Tegoprubart Islet Cell Transplant Trial in Type 1 Diabetes
Eledon Pharmaceuticals Announces Islet Cell Transplantation Ind Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
THOMSON REUTERS  ·  09-03
Eledon Pharmaceuticals Announces Islet Cell Transplantation Ind Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
Clene Q2 Net Loss Widens on Higher Other Expenses
Reuters  ·  08-14
Clene Q2 Net Loss Widens on Higher Other Expenses
Eledon Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-14
Eledon Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Eledon Pharma Q2 EPS $(0.27) Misses $(0.16) Estimate
Benzinga Earnings  ·  08-14
Eledon Pharma Q2 EPS $(0.27) Misses $(0.16) Estimate
Eledon Pharmaceuticals Q2 Net Loss Widens on Warrant Liability Changes
Reuters  ·  08-14
Eledon Pharmaceuticals Q2 Net Loss Widens on Warrant Liability Changes
Eledon Q2 FY26 Net Loss Widens to $31.6 Million
Reuters  ·  08-14
Eledon Q2 FY26 Net Loss Widens to $31.6 Million
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
THOMSON REUTERS  ·  08-14
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Eledon Pharmaceuticals Q2 Operating Expenses USD 22.869 Million
THOMSON REUTERS  ·  08-14
Eledon Pharmaceuticals Q2 Operating Expenses USD 22.869 Million
Eledon Pharmaceuticals Inc Expected to Post a Loss of 16 Cents a Share - Earnings Preview
Reuters  ·  08-10
Eledon Pharmaceuticals Inc Expected to Post a Loss of 16 Cents a Share - Earnings Preview

Introduction

Company Name.
Eledon Pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Issue price:
--